119 related articles for article (PubMed ID: 6469506)
1. Chemical characterization of ASTA Z 7557 (INN mafosfamide, CIS-4-sulfoethylthio-cyclophosphamide), a stable derivative of 4-hydroxy-cyclophosphamide.
Niemeyer U; Engel J; Scheffler G; Molge K; Sauerbier D; Weigert W
Invest New Drugs; 1984; 2(2):133-9. PubMed ID: 6469506
[TBL] [Abstract][Full Text] [Related]
2. Activation mechanisms of mafosfamide and the role of thiols in cyclophosphamide metabolism.
Kwon CH; Borch RF; Engel J; Niemeyer U
J Med Chem; 1987 Feb; 30(2):395-9. PubMed ID: 3806619
[TBL] [Abstract][Full Text] [Related]
3. NMR spectroscopic studies of intermediary metabolites of cyclophosphamide. A comprehensive kinetic analysis of the interconversion of cis- and trans-4-hydroxycyclophosphamide with aldophosphamide and the concomitant partitioning of aldophosphamide between irreversible fragmentation and reversible conjugation pathways.
Zon G; Ludeman SM; Brandt JA; Boyd VL; Ozkan G; Egan W; Shao KL
J Med Chem; 1984 Apr; 27(4):466-85. PubMed ID: 6708049
[TBL] [Abstract][Full Text] [Related]
4. Antiproliferative activity of 2-[N, N-bis-(2-chloroethyl)-amino]-4-[2-sulfonato-ethylthio]-tetrah ydr o-2H-1 , 3,2-oxazaphosphorine-2-oxide cyclohexamine (ASTA Z 7557, INN mafosfamide) against human and murine tumor cells in vitro.
Kovach JS; Svingen PA
Invest New Drugs; 1984; 2(2):155-9. PubMed ID: 6469509
[TBL] [Abstract][Full Text] [Related]
5. Comparative in vitro cytotoxicity of cyclophosphamide, its major active metabolites and the new oxazaphosphorine ASTA Z 7557 (INN mafosfamide).
Alberts DS; Einspahr JG; Struck R; Bignami G; Young L; Surwit EA; Salmon SE
Invest New Drugs; 1984; 2(2):141-8. PubMed ID: 6469507
[TBL] [Abstract][Full Text] [Related]
6. The key role of hydroxylation for the cytostatic activity and selectivity of cyclophosphamide.
Hilgard P; Brock N
Invest New Drugs; 1984; 2(2):131-2. PubMed ID: 6469505
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and toxicity of 4-(2-sulfonatoethylthio)-cyclophosphamide cyclohexylamine salt (ASTA Z 7557, INN mafosfamide) after intraperitoneal administration to mice.
Roberts JD; Hacker MP; Newman RA; McCormack JJ; Krakoff IH
Invest New Drugs; 1984; 2(2):215-20. PubMed ID: 6469517
[TBL] [Abstract][Full Text] [Related]
8. Phase-I study of mafosfamide-cyclohexylamine (ASTA-Z-7557, NSC 345 842) and limited phase-I data on mafosfamide-lysine.
Bruntsch U; Groos G; Hiller TA; Wandt H; Tigges FJ; Gallmeier WM
Invest New Drugs; 1985; 3(3):293-6. PubMed ID: 4066222
[TBL] [Abstract][Full Text] [Related]
9. 5-Fluoro- and 5-chlorocyclophosphamide: synthesis, metabolism, and antitumor activity of the cis and trans isomers.
Foster AB; Jarman M; Kinas RW; van Maanen JM; Taylor GN; Gaston JL; Parkin A; Richardson AC
J Med Chem; 1981 Dec; 24(12):1399-403. PubMed ID: 7310816
[TBL] [Abstract][Full Text] [Related]
10. The problem of oncostatic specificity of cyclophosphamide (NSC-26271): Studies on reactions that control the alkylating and cytotoxic activity.
Hohorst HJ; Draeger U; Peter G; Voelcker G
Cancer Treat Rep; 1976 Apr; 60(4):309-15. PubMed ID: 1277206
[TBL] [Abstract][Full Text] [Related]
11. In situ preparation and fate of cis-4-hydroxycyclophosphamide and aldophosphamide: 1H and 31P NMR evidence for equilibration of cis- and trans-4-hydroxycyclophosphamide with aldophosphamide and its hydrate in aqueous solution.
Borch RF; Hoye TR; Swanson TA
J Med Chem; 1984 Apr; 27(4):490-4. PubMed ID: 6708051
[TBL] [Abstract][Full Text] [Related]
12. The mechanism of activation of 4-hydroxycyclophosphamide.
Borch RF; Millard JA
J Med Chem; 1987 Feb; 30(2):427-31. PubMed ID: 3806624
[TBL] [Abstract][Full Text] [Related]
13. Experimental toxicology of ASTA Z 7557 (INN mafosfamide).
Pohl J; Hilgard P; Jahn W; Zechel HJ
Invest New Drugs; 1984; 2(2):201-6. PubMed ID: 6469515
[TBL] [Abstract][Full Text] [Related]
14. NMR spectroscopic studies of intermediary metabolites of cyclophosphamide. 2. Direct observation, characterization, and reactivity studies of iminocyclophosphamide and related species.
Boyd VL; Summers MF; Ludeman SM; Egan W; Zon G; Regan JB
J Med Chem; 1987 Feb; 30(2):366-74. PubMed ID: 3806617
[TBL] [Abstract][Full Text] [Related]
15. Spectroscopic detection of iminocyclophosphamide and its possible role in cyclophosphamide metabolism.
Kwon CH; Kirk MC; Struck RF; Borch RF
J Med Chem; 1987 Jun; 30(6):1110-4. PubMed ID: 3585908
[TBL] [Abstract][Full Text] [Related]
16. Base-catalyzed hydrolysis of 4-hydroperoxycyclophosphamide: evidence for iminocyclophosphamide as an intermediate.
Borch RF; Getman KM
J Med Chem; 1984 Apr; 27(4):485-90. PubMed ID: 6708050
[TBL] [Abstract][Full Text] [Related]
17. Chemical and biological evaluation of hydrolysis products of cyclophosphamide.
Gilard V; Martino R; Malet-Martino MC; Kutscher B; Müller A; Niemeyer U; Pohl J; Polymeropoulos EE
J Med Chem; 1994 Nov; 37(23):3986-93. PubMed ID: 7966159
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and antitumor activity of cyclophosphamide analogues. 3. Preparation, molecular structure determination and anticancer screening of racemic cis- and trans-4-phenylcyclophosphamide.
Boyd VL; Zon G; Himes VL; Stalick JK; Mighell AD; Secor HV
J Med Chem; 1980 Apr; 23(4):372-5. PubMed ID: 7381836
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of human B lymphocyte differentiation by a stable metabolite of cyclophosphamide (ASTA Z 7557, INN mafosfamide).
Gorski A; Korczak-Kowalska G
Invest New Drugs; 1984; 2(2):227-9. PubMed ID: 6236164
[TBL] [Abstract][Full Text] [Related]
20. Effect of ASTA Z 7557 (INN mafosfamide) a precursor of 4-hydroxy-cyclophosphamide on human T-lymphocytes' Fc-receptors and immunoregulatory functions.
Saal JG; Hadam M; Frank F; Rautenstrauch H; Fritz P
Invest New Drugs; 1984; 2(2):231-5. PubMed ID: 6236165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
